| Document |
Document Title |
|
WO/2002/098849A2 |
Disclosed are compounds of formula X, where R¿n?, R¿20?, R¿1?, R¿2?, R¿3?, and R¿c? are defined herein. These compounds are useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions comprising c...
|
|
WO/2002/096864A1 |
The invention relates to carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments, physiologically-acceptable salts and physiologically-functional derivatives thereof. Compounds of formula (I), in w...
|
|
WO/2002/096884A2 |
The invention relates to novel substituted benzoylketones of formula (I), in which Q = O (oxygen) or S (sulphur), R?1¿ - R?5¿ and Z have the meaning given in the description and several methods for production thereof and use thereof as...
|
|
WO/2002/096863A1 |
The present invention relates to certain phenalkyloxy-phenyl derivatives of formula (I) and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for ...
|
|
WO/2002/096876A1 |
Disclosed are novel aromatic compounds of the formula (I) described herein, wherein G, E, W, Ar, X, Y and Z are disclosed herein. The compounds are useful for treating cytokine mediated diseases or conditions such as chronic inflammatory...
|
|
WO/2002/092574A1 |
The invention relates to novel substituted benzoylcyclohexenones of formula (I), in which Q, R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, Y and Z are defined as per the description. The invention also relates to a method for their production and t...
|
|
WO2002038534A3 |
The invention relates to novel compounds which are substituted alkyldiamino derivatives of formula (I). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions con...
|
|
WO/2002/090336A1 |
The invention relates to novel arylketones of formula (I) wherein A?1¿, A?2¿, Q, R?1¿, R?2¿, X, Y and Z have the meaning cited in the description, the use thereof as herbicides and to methods and intermediate products for the product...
|
|
WO/2002/085838A1 |
The present invention relaters to copper-catalyzed carbon-heteroatom and carbon-carbon bond-forming methods. In certain embodiments, the present invention relates to copper-catalyzed methods of forming a carbon-nitrogen bond between the ...
|
|
WO/2002/085829A1 |
A process for production of dimers of aromatic monohydroxyl compounds, characterized by conducting the oxidative coupling of an aromatic compound represented by the general formula [I]: Ar-OH [I] (wherein Ar is an optionally substituted ...
|
|
WO/2002/085836A1 |
A binaphtol derivative represented by the following general formula [1]: [1] and a salt of the derivative.
|
|
WO2001070675A3 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
WO2001058855A9 |
Substituted phenylalanines are provided comprising an hydantoin, urea or 2-hydroxyl, 2-methylpropionyl group, dimers thereof and alkyl, polyfluoroamido and haloarylamino derivatives thereof, as well as radiolabeled derivatives thereof. T...
|
|
WO/2002/083627A2 |
The invention relates to the novel biphenyl derivatives of the general formula (I), wherein R1, R1', R1'', R2 and n are defined as in claim 1. The invention also relates to the stereoisomers and the physiologically acceptable salts or so...
|
|
WO2002062763A3 |
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
|
|
WO/2002/078686A1 |
The invention relates to the use of retinyl carbonates of formula (I), wherein R represents an optionally substituted C¿1?-C¿12? alkyl, C¿6?-C¿12? aryl, C¿7?-C¿13? aralkyl or a group of formula (II), for the cosmetic treatment of t...
|
|
WO/2002/076402A2 |
The invention provides conjugates of fatty amines and pharmaceutical agents useful in treating cancers, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparations of the fatty amine-pharmaceuti...
|
|
WO/2002/076930A2 |
Substituted diarylureas, pharmaceutical compositions containing them, and their use for stimulating Fas-mediated apoptosis. The compounds, as single stereoisomers or mixtures of stereoisomers, their pharmaceutically acceptable salts, and...
|
|
WO/2002/076929A1 |
In one embodiment, this invention provides a novel class of compounds as antagonists of the MCH receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more of the compounds, methods of preparing phar...
|
|
WO2002044126A3 |
The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins. In the compounds of this invention, at least two carbo-or heterocyclic groups are attached ...
|
|
WO/2002/072534A2 |
The invention relates novel butane acid derivatives containing a cyanide group, pharmaceutical compositions containing butane acid derivatives and the use of said butane acid derivatives in the production of pharmaceutical compositions f...
|
|
WO2002053534A8 |
Compounds represented by the general formula (I) or salts thereof, and medicines containing the same: (I) [wherein W is W-A<1>-W- (wherein W is optionally substituted aryl or the like; A<1> is -NR<1>-, a single bond, -C(O)-, or the like;...
|
|
WO/2002/072536A1 |
The invention relates to novel compounds having Vanilloid Receptor (VR1) antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders.
|
|
WO2002030876A3 |
The present invention relates to compounds of the general formula (I), process for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of...
|
|
WO2001007020A3 |
The invention relates to the use of carboxylic acid amides of general formula (I) for inhibiting telomerase, wherein A, B and R1 to R5 are defined as per claim (1). The invention also relates to novel carboxylic acid amides of general fo...
|
|
WO/2002/072083A1 |
The nonenzymatic glycation and crosslinking of proteins is a part of the aging process with the glycation endproducts and crosslinking of long-lived proteins increasing with age. This process is increased at elevated concentrations of re...
|
|
WO/2002/070493A1 |
The invention relates to a bisaryl derivative of the formula I, wherein (R, R) is selected from (H, H), O, (H, CH¿3?), (H, OH) and (H, CN); Ar is substituted phenyl; and A is a group of following formula II, III, IV or V: The compounds ...
|
|
WO/2002/070471A1 |
Compounds of the formula (I) in which R?1¿ is CN, or C(=NH)-NH¿2?, CON(R?3¿)¿2? or [C(R?4¿)¿2?]¿n?N(R?3¿)¿2?, each of which is unsubstituted or monosubstituted by C(=O)R?3¿, COOR?3¿, or?3¿ or by a conventional amino-protectin...
|
|
WO/2002/070467A1 |
The invention relates to new diphenylurea having the formula (I) or a salt thereof, where Y is CO=O, C=S, C=NH, (C=O)¿2? or SO¿2?; and to processes for the preparation of these compounds and to their use in the treatment of protozoal d...
|
|
WO/2002/068380A1 |
The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.
|
|
WO2002012534A3 |
The present invention relates to compounds made by a subset of modules from one or more polyketide synthase ("PKS") genes that are used as starting material in the chemical synthesis of novel molecules, particularly naturally occurring p...
|
|
WO2000066104A9 |
ACE-2 inhibiting compounds are disclosed. Methods of using the compounds and pharmaceutical compositions containing the compounds are also claimed.
|
|
WO2002002520A3 |
The present invention is disubstituted amines of formula (I) and disubstituted amines of formula (II) useful in treating Alzheimer's disease and other similar diseases.
|
|
WO2000067746A9 |
A method for the inhibition of the binding of alpha 4 beta 1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions com...
|
|
WO2002002506A3 |
The present invention is substituted amines of formula (XV) useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2002/064139A1 |
This invention relates to the use of the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity for the treatment of Parkinson's disease.
|
|
WO/2002/064128A1 |
The invention relates to the use of a compound that modulates the association of caspase-9 to Apaf-1 for the treatment of diseases characterized by excessive or insufficient cell death.
|
|
WO/2002/064549A1 |
PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certan plasma lipid levels, including high density liporprotein-cholesterol and to lower certain other plasma lipid lev...
|
|
WO/2002/064130A1 |
PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipo-protein-cholesterol and to lower certain plasma lipid levels, ...
|
|
WO/2002/062763A2 |
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
|
|
WO/2002/062762A2 |
Compounds of formula (I) are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
|
|
WO2002002518A3 |
The present invention is disubstituted amines of formula (I) and disbustituted amines of formula (II) useful in treating Alzheimer's disease and other similar diseases.
|
|
WO2002006189A3 |
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salt and/or pharmaceutically acceptable esters thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associa...
|
|
WO/2002/059077A1 |
It is intended to provide drugs which have cholesteryl ester transfer protein inhibitory effect and are useful as blood lipid lowering agent, etc. Namely, compounds represented by the following general formula (I), salts thereof, and med...
|
|
WO/2002/059080A2 |
The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invent...
|
|
WO2002002505A3 |
The present invention is substituted amines of formula (X) useful in treating Alzheimer's disease and other similar diseases.
|
|
WO/2002/059102A2 |
The invention concerns novel products of formula (I) wherein: Y represents oxygen or sulphur; Z represents C=CH2, CH-CH3 or CH2; R1 represents hydrogen, morpholinyl or the radical (II) wherein the two nitrogen atoms are linear or form a ...
|
|
WO/2002/059081A2 |
Urea and amide derivatives inhibit cell function of the chemokine receptor CCR-3. These compounds offer an effective means for treating a range of diseases thought to be mediated by the CCR-3 receptor. A variety of useful area and amide ...
|
|
WO/2002/057242A2 |
Novel antagonists of &agr 4β1 integrin and/or &agr 4β7 integrin of the general Formula (I): wherein R1, R2, R5, L1, L2, Rb, W and Z are as defined in any one of claims 1 to 13, A represents -CH- or a nitrogen atom, and p is from 0 to 4.
|
|
WO/2002/057233A1 |
The present invention related to compounds of the formula (I) or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof; which are useful for the ...
|
